SNAI1 is critical for the aggressiveness of prostate cancer cells with low E-cadherin

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Deep, Gagan ^a,b   Jain, Anil K ^a   Ramteke, Anand ^a,c   Ting, Harold ^a   Vijendra, Kavitha C ^a   Gangar, Subhash C ^a   Agarwal, Chapla ^a,b   Agarwal, Rajesh ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c TEZPUR UNIVERSITY   (India)

Author keywords

E cadherin; EMT; Prostate cancer; SNAI1; Stemness

Indexed keywords

BETA CATENIN; BETA3 INTEGRIN; CD44V ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOTCH1 RECEPTOR; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EGR 1; TRANSCRIPTIONAL REPRESSOR SNAI1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; CANCER CELL; CANCER GROWTH; CELL ADHESION; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; CLONOGENESIS; CLONOGENIC ASSAY; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; GROWTH RATE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR INVASION; TUMOR XENOGRAFT; WESTERN BLOTTING;

MUS MUSCULUS;

ANIMALS; BLOTTING, WESTERN; CADHERINS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84896729650     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-37     Document Type: Article

References (74)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30. 10.3322/caac.21166, 23335087.
2. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther 2007, 6:2609-2617. 10.1158/1535-7163.MCT-07-0234, 17938257.
3. Tantivejkul K, Kalikin LM, Pienta KJ. Dynamic process of prostate cancer metastasis to bone. J Cell Biochem 2004, 91:706-717. 10.1002/jcb.10664, 14991762.
4. Hadaschik BA, Gleave ME. Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol 2007, 25:413-419. 10.1016/j.urolonc.2007.05.010, 17826663.
5. Ye XC, Choueiri M, Tu SM, Lin SH. Biology and clinical management of prostate cancer bone metastasis. Front Biosci 2007, 12:3273-3286. 10.2741/2311, 17485298.
6. Saad F, Markus R, Goessl C. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases. BJU Int 2008, 101:1071-1075. 10.1111/j.1464-410X.2007.07364.x, 18070191.
7. Msaouel P, Pissimissis N, Halapas A, Koutsilieris M. Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Pract Res Clin Endocrinol Metab 2008, 22:341-355. 10.1016/j.beem.2008.01.011, 18471791.
8. Buijs JT, van der Pluijm G. Osteotropic cancers: from primary tumor to bone. Cancer Lett 2009, 273:177-193. 10.1016/j.canlet.2008.05.044, 18632203.
9. Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev 2010, 29:447-463. 10.1007/s10555-010-9237-0, 3928361, 20714788.
10. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007, 39:305-318. 10.1080/00313020701329914, 17558857.
11. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006, 66:8319-8326. 10.1158/0008-5472.CAN-06-0410, 16951136.
12. Drasin DJ, Robin TP, Ford HL. Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity. Breast Cancer Res 2011, 13:226. 10.1186/bcr3037, 3326549, 22078097.
13. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659. 10.1016/j.cell.2009.06.034, 19682730.
14. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715. 10.1016/j.cell.2008.03.027, 2728032, 18485877.
15. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009, 9:265-273. 10.1038/nrc2620, 19262571.
16. Baranwal S, Alahari SK. Molecular mechanisms controlling E-cadherin expression in breast cancer. Biochem Biophys Res Commun 2009, 384:6-11. 10.1016/j.bbrc.2009.04.051, 2700729, 19379710.
17. Jiang YG, Luo Y, He DL, Li X, Zhang LL, Peng T, Li MC, Lin YH. Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha. Int J Urol 2007, 14:1034-1039. 10.1111/j.1442-2042.2007.01866.x, 17956532.
18. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer 2007, 7:415-428. 10.1038/nrc2131, 17508028.
19. Du C, Zhang C, Hassan S, Biswas MH, Balaji KC. Protein kinase D1 suppresses epithelial-to-mesenchymal transition through phosphorylation of snail. Cancer Res 2010, 70:7810-7819. 10.1158/0008-5472.CAN-09-4481, 20940406.
20. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994, 54:3929-3933.
21. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma HE, Debruyne FM, Isaacs WB. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992, 52:5104-5109.
22. Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG. Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol 1996, 148:1375-1380. 1861553, 8623909.
23. Whiteland H, Spencer-Harty S, Thomas DH, Davies C, Morgan C, Kynaston H, Bose P, Fenn N, Lewis P, Bodger O, Jenkins S, Doak SH. Putative prognostic epithelial-to- mesenchymal transition biomarkers for aggressive prostate cancer. Exp Mol Pathol 2013, 95:220-226. 10.1016/j.yexmp.2013.07.010, 23933194.
24. Emadi Baygi M, Soheili ZS, Schmitz I, Sameie S, Schulz WA. Snail regulates cell survival and inhibits cellular senescence in human metastatic prostate cancer cell lines. Cell Biol Toxicol 2010, 26:553-567. 10.1007/s10565-010-9163-5, 20397042.
25. McKeithen D, Graham T, Chung LW, Odero-Marah V. Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells. Prostate 2010, 70:982-992. 2877267, 20166136.
26. Heeboll S, Borre M, Ottosen PD, Dyrskjot L, Orntoft TF, Torring N. Snail1 is over-expressed in prostate cancer. APMIS 2009, 117:196-204. 10.1111/j.1600-0463.2008.00007.x, 19245592.
27. Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA, Gouvin LM, Sharma VM, Mercurio AM. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 2010, 17:319-332. 10.1016/j.ccr.2010.02.030, 2881822, 20385358.
28. Hwang WL, Yang MH, Tsai ML, Lan HY, Su SH, Chang SC, Teng HW, Yang SH, Lan YT, Chiou SH, Wang HW. SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. Gastroenterology 2011, 141:279-291. 291 e271-275, 10.1053/j.gastro.2011.04.008, 21640118.
29. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008, 98:756-765. 10.1038/sj.bjc.6604242, 2259168, 18268494.
30. Bisson I, Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 2009, 19:683-697. 10.1038/cr.2009.43, 19365403.
31. Guzman-Ramirez N, Voller M, Wetterwald A, Germann M, Cross NA, Rentsch CA, Schalken J, Thalmann GN, Cecchini MG. In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate 2009, 69:1683-1693. 10.1002/pros.21018, 19644960.
32. Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, Mistree T, Thomas SB, Farrar WL. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 2009, 26:433-446. 10.1007/s10585-009-9242-2, 2782741, 19221883.
33. Kawasaki BT, Hurt EM, Kalathur M, Duhagon MA, Milner JA, Kim YS, Farrar WL. Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: an integrated molecular profiling approach. Prostate 2009, 69:827-837. 10.1002/pros.20931, 2700306, 19204913.
34. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006, 25:1696-1708. 10.1038/sj.onc.1209327, 16449977.
35. Handorean AM, Yang K, Robbins EW, Flaig TW, Iczkowski KA. Silibinin suppresses CD44 expression in prostate cancer cells. Am J Transl Res 2009, 1:80-86. 2776293, 19966941.
36. Deep G, Gangar SC, Agarwal C, Agarwal R. Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells. Cancer Prev Res (Phila) 2011, 4:1222-1232. 10.1158/1940-6207.CAPR-10-0370, 3151351, 21546539.
37. Saad F, Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 2010, 36:177-184. 10.1016/j.ctrv.2009.11.005, 20015594.
38. Eaton CL, Colombel M, van der Pluijm G, Cecchini M, Wetterwald A, Lippitt J, Rehman I, Hamdy F, Thalman G. Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate 2010, 70:875-882.
39. Webber MM, Quader ST, Kleinman HK, Bello-DeOcampo D, Storto PD, Bice G, DeMendonca-Calaca W, Williams DE. Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression. Prostate 2001, 47:1-13. 10.1002/pros.1041, 11304724.
40. van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci 2008, 65:3756-3788. 10.1007/s00018-008-8281-1, 18726070.
41. Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Celiktas M, Hwang MS, Darling DS, Coleman IM, Nelson PS, Nguyen HM, Corey E, Tewari M, Morrissey C, Vessella RL, Knudsen BS. Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol 2011, 179:400-410. 10.1016/j.ajpath.2011.03.028, 3123858, 21703419.
42. Saha B, Arase A, Imam SS, Tsao-Wei D, Naritoku WY, Groshen S, Jones LW, Imam SA. Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone. Prostate 2008, 68:78-84. 10.1002/pros.20670, 18008331.
43. Pontes J, Srougi M, Borra PM, Dall' Oglio MF, Ribeiro-Filho LA, Leite KR. E-cadherin and beta-catenin loss of expression related to bone metastasis in prostate cancer. Appl Immunohistochem Mol Morphol 2010, 18:179-184. 10.1097/PAI.0b013e3181640bca, 18685493.
44. Rubin MA, Mucci NR, Figurski J, Fecko A, Pienta KJ, Day ML. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol 2001, 32:690-697. 10.1053/hupa.2001.25902, 11486167.
45. De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 1999, 53:707-713. 10.1016/S0090-4295(98)00577-9, 10197845.
46. Fan XJ, Wan XB, Yang ZL, Fu XH, Huang Y, Chen DK, Song SX, Liu Q, Xiao HY, Wang L, Wang JP. Snail promotes lymph node metastasis and Twist enhances tumor deposit formation through epithelial-mesenchymal transition in colorectal cancer. Hum Pathol 2013, 44:173-180. 10.1016/j.humpath.2012.03.029, 22974478.
47. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ, Notorfrancesco KL, Cardiff RD, Chodosh LA. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 2005, 8:197-209. 10.1016/j.ccr.2005.07.009, 16169465.
48. Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH, Cote RJ. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006, 12:5615-5621. 10.1158/1078-0432.CCR-06-0169, 17020963.
49. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009, 11:R46. 10.1186/bcr2333, 2750105, 19589136.
50. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005, 5:744-749. 10.1038/nrc1694, 16148886.
51. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality?. Nat Med 2009, 15:1010-1012. 10.1038/nm0909-1010, 19734877.
52. Li H, Tang DG. Prostate cancer stem cells and their potential roles in metastasis. J Surg Oncol 2011, 103:558-562. 10.1002/jso.21806, 21480250.
53. van der Pluijm G. Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone 2011, 48:37-43. 10.1016/j.bone.2010.07.023, 20670698.
54. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008, 3:e2888. 10.1371/journal.pone.0002888, 2492808, 18682804.
55. Celia-Terrassa T, Meca-Cortes O, Mateo F, de Paz AM, Rubio N, Arnal-Estape A, Ell BJ, Bermudo R, Diaz A, Guerra-Rebollo M, Lozano JJ, Estaras C, Ulloa C, Alvarez-Simon D, Mila J, Vilella R, Paciucci R, Martinez-Balbas M, de Herreros AG, Gomis RR, Kang Y, Blanco J, Fernandez PL, Thomson TM. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J Clin Invest 2012, 122:1849-1868. 10.1172/JCI59218, 3366719, 22505459.
56. Foubert E, De Craene B, Berx G. Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression. Breast Cancer Res 2010, 12:206. 10.1186/bcr2585, 2917026, 20594364.
57. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412:822-826. 10.1038/35090585, 11518967.
58. Odero-Marah VA, Wang R, Chu G, Zayzafoon M, Xu J, Shi C, Marshall FF, Zhau HE, Chung LW. Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res 2008, 18:858-870. 10.1038/cr.2008.84, 18645583.
59. Barnett P, Arnold RS, Mezencev R, Chung LW, Zayzafoon M, Odero-Marah V. Snail-mediated regulation of reactive oxygen species in ARCaP human prostate cancer cells. Biochem Biophys Res Commun 2011, 404:34-39. 10.1016/j.bbrc.2010.11.044, 3021188, 21093414.
60. Neal CL, McKeithen D, Odero-Marah VA. Snail negatively regulates cell adhesion to extracellular matrix and integrin expression via the MAPK pathway in prostate cancer cells. Cell Adh Migr 2011, 5:249-257. 10.4161/cam.5.3.15618, 3210209, 21478672.
61. Neal CL, Henderson V, Smith BN, McKeithen D, Graham T, Vo BT, Odero-Marah VA. Snail transcription factor negatively regulates maspin tumor suppressor in human prostate cancer cells. BMC Cancer 2012, 12:336. 10.1186/1471-2407-12-336, 3437215, 22857708.
62. Smith BN, Odero-Marah VA. The role of Snail in prostate cancer. Cell Adh Migr 2012, 6:433-441. 10.4161/cam.21687, 3496681, 23076049.
63. Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene 2009, 28:3573-3585. 10.1038/onc.2009.214, 19633685.
64. Beach S, Tang H, Park S, Dhillon AS, Keller ET, Kolch W, Yeung KC. Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene 2008, 27:2243-2248. 10.1038/sj.onc.1210860, 2933472, 17952120.
65. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung MC. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004, 6:931-940. 10.1038/ncb1173, 15448698.
66. Yang Z, Rayala S, Nguyen D, Vadlamudi RK, Chen S, Kumar R. Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions. Cancer Res 2005, 65:3179-3184.
67. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 2009, 15:416-428. 10.1016/j.ccr.2009.03.016, 2881229, 19411070.
68. Roy HK, Kunte DP, Koetsier JL, Hart J, Kim YL, Liu Y, Bissonnette M, Goldberg M, Backman V, Wali RK. Chemoprevention of colon carcinogenesis by polyethylene glycol: suppression of epithelial proliferation via modulation of SNAIL/beta-catenin signaling. Mol Cancer Ther 2006, 5:2060-2069. 10.1158/1535-7163.MCT-06-0054, 16928827.
69. Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P, Mukhtar H. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004, 64:3334-3343. 10.1158/0008-5472.CAN-03-2422, 15126378.
70. Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2008, 68:6822-6830. 10.1158/0008-5472.CAN-08-1332, 2587411, 18701508.
71. Harney AS, Meade TJ, LaBonne C. Targeted inactivation of Snail family EMT regulatory factors by a Co(III)-Ebox conjugate. PLoS One 2012, 7:e32318. 10.1371/journal.pone.0032318, 3290632, 22393397.
72. Zi X, Feyes DK, Agarwal R. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin Cancer Res 1998, 4:1055-1064.
73. Kaur M, Velmurugan B, Tyagi A, Deep G, Katiyar S, Agarwal C, Agarwal R. Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft. Mol Cancer Ther 2009, 8:2366-2374. 10.1158/1535-7163.MCT-09-0304, 2728169, 19638451.
74. Singh RP, Deep G, Chittezhath M, Kaur M, Dwyer-Nield LD, Malkinson AM, Agarwal R. Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst 2006, 98:846-855. 10.1093/jnci/djj231, 16788158.